What is Artificial Intelligence In Diabetes Management?
Artificial Intelligence in Diabetes Software refers to algorithms and software used in the investigation of complex medical data for diabetic patients. Artificial Intelligence refers to gathering information, processing it and giving a precise output to the customers. Software companies are introducing numerous applications catering to diabetes management. These find application in controlling and managing diabetes. Growing use of mobile phones and other digital platforms by companies to design such applications are the key factors growing artificial intelligence in the diabetes management market
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Unit | Value (USD Million) |
Key Companies Profiled | Apple Inc. (United States), Diabnext (China), Glooko Inc. (United States), IBM Corporation (United States), Tidepool (United States), Google, Inc. (United States), Vodafone Group Plc. (United Kingdom) and Bigfoot Biomedical (United States) |
The study covers a detailed analysis segmented by key business segments i.e. , by application (Automated Retinal Screening, Clinical Decision Support, Predictive Population Risk Stratification, Patient Self-Management Tools and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Artificial Intelligence In Diabetes Management market throughout the predicted period.
The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the markets competitive landscape and offers information on the products offered by various leading companies. Additionally, this Artificial Intelligence In Diabetes Management market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.
The report offers several leading Players, some of them are Apple Inc. (United States), Diabnext (China), Glooko Inc. (United States), IBM Corporation (United States), Tidepool (United States), Google, Inc. (United States), Vodafone Group Plc. (United Kingdom) and Bigfoot Biomedical (United States).
Market Overview:
In March 2022 Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can work together to improve health outcomes.
As part of the AI/ML Action Plan, the FDA is highlighting its intention to develop an update to the proposed regulatory framework presented in the AI/ML-based SaMD discussion paper, including through the issuance of draft guidance on the predetermined change control plan.
Artificial intelligence in diabetes software management is growing owing to technological development and product innovation such as mobile applications to analyze glucose level. The market is expected to witness collaborations among, IT and healthcare companies, to enhance patient user experience, thereby boosting acceptance.
Artificial Intelligence In Diabetes Management Market Dynamics:
Attributes | Details |
---|
Growth Drivers | - Unhealthy Lifestyle Leading to Increasing Number of Patient with Diabetes
- Growing Geriatric Population
|
Major Trends | - The Emergence of Mobile Technology in Diabetes Management
|
Restraints | - High Cost Associated with Artificial Intelligence in Diabetes Software Management
- Inability of People to Operate Mobile Applications
|
Road Blocks / Challenges | - Privacy and Data Safety Concerns
|
Gaps & Opportunities | - Technological Development and Product Innovations
|
Key highlights of the Global Artificial Intelligence In Diabetes Management market Study:
CAGR of the market during the forecast period 2021-2027
In-depth information on growth factors that will accelerate the Artificial Intelligence In Diabetes Management market in next few years.
Detailed Insights on futuristic trends and changing consumer behavior
Forecast of the Global Artificial Intelligence In Diabetes Management market size and its contribution to the parent market by type, application and by country.
A broad view of customer demand
Uncover markets competitive landscape and in-depth information on various Players
Comprehensive information about factors that will challenge the growth of Artificial Intelligence In Diabetes Management Players
Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
A tipping point in globalization
A major slowdown in Western economies
Significant shifts in technology and cost structure
The challenges of regulatory compliance
New forms of competition developing
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Artificial Intelligence In Diabetes Management market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Artificial Intelligence In Diabetes Management market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Healthcare Institutes, Research Organizations and Consulting Companies, Organizations, Associations and Alliances Related to Artificial Intelligence in Diabetes Software, Government Bodies Such As Regulating Authorities and Policy Makers., Industry Associations, Market Research and Consulting Firms and Others.
This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.